Recent advances in hyperthermia therapy‐based synergistic immunotherapy

M Chang, Z Hou, M Wang, C Li, J Lin - Advanced Materials, 2021 - Wiley Online Library
The past decades have witnessed hyperthermia therapy (HTT) as an emerging strategy
against malignant tumors. Nanomaterial‐based photothermal therapy (PTT) and magnetic …

[HTML][HTML] Immunotherapy for colorectal cancer

S Koido, T Ohkusa, S Homma, Y Namiki… - World journal of …, 2013 - ncbi.nlm.nih.gov
The incidence of colorectal cancer (CRC) is on the rise, and the prognosis for patients with
recurrent or metastatic disease is extremely poor. Although chemotherapy and radiation …

Functionalized carbon nanotubes for potential medicinal applications

Y Zhang, Y Bai, B Yan - Drug discovery today, 2010 - Elsevier
Functionalized carbon nanotubes display unique properties that enable a variety of
medicinal applications, including the diagnosis and treatment of cancer, infectious diseases …

[HTML][HTML] Impact of the immune system and immunotherapy in colorectal cancer

JL Markman, SL Shiao - Journal of gastrointestinal oncology, 2015 - ncbi.nlm.nih.gov
The development of cancer is a multi-step process involving the gradual loss of regulation
over the growth and functional capabilities of normal cells. Much research has been focused …

Translating tumor antigens into cancer vaccines

L Buonaguro, A Petrizzo, ML Tornesello… - Clinical and Vaccine …, 2011 - Am Soc Microbiol
Vaccines represent a strategic successful tool used to prevent or contain diseases with high
morbidity and/or mortality. However, while vaccines have proven to be effective in combating …

Antigen-specific vaccines for cancer treatment

M Tagliamonte, A Petrizzo, ML Tornesello… - Human vaccines & …, 2014 - Taylor & Francis
Vaccines targeting pathogens are generally effective and protective because based on
foreign non-self antigens which are extremely potent in eliciting an immune response. On …

Whole-cell cancer vaccination: from autologous to allogeneic tumor-and dendritic cell-based vaccines

TD De Gruijl, AJM Van Den Eertwegh… - Cancer Immunology …, 2008 - Springer
The field of tumor vaccination is currently undergoing a shift in focus, from individualized
tailor-made vaccines to more generally applicable vaccine formulations. Although primarily …

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer

J Berek, P Taylor, W McGuire, LM Smith… - Journal of Clinical …, 2009 - ascopubs.org
Purpose This phase III study tested the hypothesis that the CA-125–specific murine
monoclonal antibody, oregovomab, administered as a monoimmunotherapy after front-line …

Immunotherapy for ovarian cancer: what's next?

LE Kandalaft, DJ Powell Jr, N Singh… - Journal of Clinical …, 2011 - ascopubs.org
In the past decade, we have witnessed important gains in the treatment of ovarian cancer;
however, additional advances are required to reduce mortality. With compelling evidence …

Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment

SN Markovic, LA Erickson, RD Rao, RH Weenig… - Mayo Clinic …, 2007 - Elsevier
Critical to the clinical management of a patient with malignant melanoma is an
understanding of its natural history. As with most malignant disorders, prognosis is highly …